Literature DB >> 17332526

Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women.

A Corbould1.   

Abstract

Adipose tissue plays a central role in determining whole body insulin sensitivity. Several aspects of adipose cell function are regulated by androgens. Given that high androgen levels and insulin resistance are linked in women, we proposed that androgens may influence insulin-mediated glucose metabolism in adipose cells. Preadipocytes harvested from s.c. adipose tissue of healthy women aged 37 +/- 5 years were differentiated in vitro, then treated with testosterone (T) and/or androgen receptor (AR) antagonists (cyproterone acetate, flutamide) for 48 h. Maximal insulin-stimulated glucose uptake (insulin 10 nM) and increment following insulin stimulation were significantly impaired in cells treated with T 10 and 100 nmol/l. This defect was abolished by cyproterone acetate and partially reversed by flutamide. The effect of T could not be accounted for by altered differentiation status of the adipocytes. In the glucose metabolic pathway of insulin signaling, treatment of cells with T 10 nmol/l did not alter insulin-stimulated phosphorylation of insulin receptor substrate-1 or Akt, but insulin-stimulated phosphorylation of protein kinase C (PKC) zeta was impaired. Insulin signaling via the mitogenic/gene regulatory pathway, as assessed by extracellular signal-regulated kinase phosphorylation, was unchanged. We conclude that (1) T, or an androgenic metabolite of T, induces insulin resistance in adipocytes of women, selective for metabolic signaling pathways; (2) this defect is via AR; and (3) the defect in signaling is independent of phosphatidylinositol 3-kinase activation and involves impaired phosphorylation of PKCzeta. These findings are relevant to understanding the pathogenesis of insulin resistance in hyperandrogenic women.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17332526     DOI: 10.1677/joe.1.07070

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  55 in total

1.  Steroidogenic regulatory factor FOS is underexpressed in polycystic ovary syndrome (PCOS) adipose tissue and genetically associated with PCOS susceptibility.

Authors:  Michelle R Jones; Gregorio Chazenbalk; Ning Xu; Angela K Chua; Tamar Eigler; Emebet Mengesha; Yen-Hao Chen; Jung-Min Lee; Marita Pall; Xiaohui Li; Yii-Der I Chen; Kent D Taylor; Ruchi Mathur; Ronald M Krauss; Jerome I Rotter; Richard S Legro; Ricardo Azziz; Mark O Goodarzi
Journal:  J Clin Endocrinol Metab       Date:  2012-06-21       Impact factor: 5.958

2.  Metabolic disorders in newly diagnosed young adult female patients with simple virilizing 21-hydroxylase deficiency.

Authors:  Hui-Jie Zhang; Jun Yang; Man-Na Zhang; Chang-Qin Liu; Min Xu; Xue-Jun Li; Shu-Yu Yang; Xiao-Ying Li
Journal:  Endocrine       Date:  2010-10-27       Impact factor: 3.633

3.  Biochemical hyperandrogenism is associated with metabolic syndrome independently of adiposity and insulin resistance in Romanian polycystic ovary syndrome patients.

Authors:  Alice Albu; Serban Radian; Simona Fica; Carmen Gabriela Barbu
Journal:  Endocrine       Date:  2014-07-15       Impact factor: 3.633

4.  Adipose Insulin Resistance in Normal-Weight Women With Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Julia D Phan; Karen L Leung; Tristan R Grogan; Xiangmiang Ding; Xinmin Li; Luis R Hoyos; David H Abbott; Gregorio D Chazenbalk
Journal:  J Clin Endocrinol Metab       Date:  2019-06-01       Impact factor: 5.958

Review 5.  Mechanisms of intergenerational transmission of polycystic ovary syndrome.

Authors:  Daniel A Dumesic; Luis R Hoyos; Gregorio D Chazenbalk; Rajanigandha Naik; Vasantha Padmanabhan; David H Abbott
Journal:  Reproduction       Date:  2020-01       Impact factor: 3.906

6.  Changes in the expression of insulin signaling pathway molecules in endometria from polycystic ovary syndrome women with or without hyperinsulinemia.

Authors:  Romina Fornes; Paulina Ormazabal; Carlos Rosas; Fernando Gabler; David Vantman; Carmen Romero; Margarita Vega
Journal:  Mol Med       Date:  2009-12-04       Impact factor: 6.354

7.  Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance.

Authors:  Theodore P Ciaraldi; Vanita Aroda; Sunder Mudaliar; R Jeffrey Chang; Robert R Henry
Journal:  J Clin Endocrinol Metab       Date:  2008-10-14       Impact factor: 5.958

8.  Relevance of an opioid, noscapine in reducing cystogeneses in rat experimental model of polycystic ovary syndrome.

Authors:  A Priyadarshani
Journal:  J Endocrinol Invest       Date:  2009-07-17       Impact factor: 4.256

Review 9.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

10.  Radiolabeling, biodistribution and gamma scintigraphy of noscapine hydrochloride in normal and polycystic ovary induced rats.

Authors:  Anjali Priyadarshani; Krishna Chuttani; Gaurav Mittal; Aseem Bhatnagar
Journal:  J Ovarian Res       Date:  2010-04-27       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.